2025 Q4
2025-11-19
Deborah H. Telman Resigned as Executive Vice President, Corporate Affairs and General Counsel
December 5, 2025
View Filing →
2025-10-30
Q3 2025 Earnings Released
Revenue and EPS announced
View Filing →
2025-10-06
Biktarvy Patent Settlement
No generic entry until April 1, 2036
View Filing →
2025 Q3
2025-08-14
New Principal Accounting Officer
Erin Burkhart appointed SVP Controllership, effective Sept 22, 2025
View Filing →
2025-08-07
Q2 2025 Earnings
Q2 2025 financial results announced
View Filing →
2025-08-04
Amended Bylaws
Board approved amended bylaws on July 30, 2025
View Filing →
2025 Q2
2025-05-08
2025 Annual Shareholder Meeting
9 directors elected, executive compensation approved, 4 shareholder proposals rejected
View Filing →
2025-04-24
Q1 2025 Earnings
Q1 2025 financial results announced
View Filing →
2025 Q1
2025-03-12
Chief Accounting Officer Departed
Sandra Patterson out, Diane Wilfong interim CAO
View Filing →
2025-02-11
Q4 2024 Earnings
Financial results for quarter and year ended December 31, 2024
View Filing →
2024 Q4
2024-11-20
Debt Offering
$3.5B senior notes: $750M 2029s at 4.80%, $1B 2035s at 5.10%, $1B 2054s at 5.50%, $750M 2064s at 5.60%
View Filing →
2024-11-06
Q3 2024 Earnings
Q3 2024 financial results announced
View Filing →
2024 Q3
2024-08-08
Q2 2024 Earnings
Q2 2024 financial results for quarter ended June 30, 2024
View Filing →
2024-07-17
CMO Departure
Merdad V. Parsey, M.D., Ph.D. leaving, transition through Q1 2025
View Filing →
2024 Q2
2024-05-09
Annual Shareholder Meeting Results
9 directors elected, officer exculpation amendment approved, 3 shareholder proposals rejected
View Filing →
2024-04-25
Q1 2024 Earnings
Q1 2024 financial results announced
View Filing →
2024 Q1
2024-03-22
Acquired CymaBay Therapeutics
$4.3B deal at $32.50 per share
View Filing →
2024-03-14
Director Retirement
Kevin E. Lofton retiring from Board at May 8, 2024 annual meeting
View Filing →
2024-02-12
Acquired CymaBay Therapeutics
$32.50 per share, $151.6M termination fee
View Filing →
2024-02-06
Q4 2023 Earnings
Financial results for quarter and year ended December 31, 2023
View Filing →